Thanks, Leo.
going or introduction little minimal molecular on So residual disease. focused to about pipeline bit and I'm disease present the give you update, guys a the residual majorly which is MRD, an
to so Rock Page publication. the representing Page turn let's XX, So basically XX clinical MRD Burning
a utilities. basically, So MRD has of lot
be before here, shown be prognosis the some also do lot after like, adjuvant effectiveness neoadjuvant like or to baseline look it monitoring basically look commonly, like of the the neoadjuvant treatment Then As either MRD at the surveillance. resection a to -- after a kind at could therapy prediction get effectiveness based or MRD assessment longitudal look like on ctDNA more value picture the treatment also use -- for a in level. can to landmark therapy also the to and that the we There can on status. at postsurgical of showing after a done
cancer, So Burning types, publications cancer Rock kind of biliary pancreatic different including that's lung gastric a cancer bunch has cell kind different as of BTC, tract cancer, cancer, related colorectal of non-small as well the cancer. to
the So are kind meetings years. them publications, clinical all actually format upcoming presented or poster most the meetings happening X shown different of in like within of in being
Cancer little non-small cancer. which Cell to wanted to give major introduction the So related I about the you bit cell a more one is is the guys lung just publication,
Let's turn XX. to Page
been we've in using technology called brief it's the -- actually called brPROPHET, we PROPHET. So
whole whole collected from the personalized determine MRD coding well we proprietary as sequencing -- got a plasma trying exome We So design the to ctDNA to is up panel basically, the it's sequencing. based on the utilize personalized tumor Then capture panel exome and mutations, use panel, XX tumor-specific. which this -- potential sequencing as ultra-deep algorithm, point that on from and MRD kind then patient -- collection. result time for of fragment the proprietary of the same type that status can patient. of blood that MRD Based that sequencing the also the
assay. brPROPHET showing right basically page the of this performance the So on is analytical
the to sample it's -- down including right uncontrived type basically diluted panel, ppm. line X of top X So about the on so cell talking
bit is As background uncontrived XX still of there's can quite a line. baseline significant -- which you to out see, we compared load difference can is which see cell here, site, different
to the kind give is this from the rare asset very fraction enough this showing low tumor confidence based very some allele detect patient. on So frequency, of us ctDNA sensitive
can on allele of detection well that right as right the from algorithm we Based load the each based of top assess site. the what's quantitative estimate can capability property panel, -- on use, ctDNA frequency patient. as assay. the bottom estimate this We showing fraction and we that's the On the
expectation but us see very showing good can definitely contrived here, lot you correlation. is estimation it showing this As a confidence of gives data, the and
the -- for on to is in Page in technology, this Cancer top-tier we utilization Cell, cancer journal hospital a lung Hospital. which on medicine. based People's XX. worked Beijing, translational move cell non-small top Basically, we we journal this top-tier So a And technology published with
X. one here, highlights. lung head-to-head see at October look in so a it's outperformed has but comparison to read fixed-panel MRD of a in been cell non-small just assay it one in you I PROPHET can don't published this want there's it. you Mostly the And cancer. As couple showing can the by
of basically you Page to study. this overview Move XX, an give
early-stage at is those patients see also, actually the collect sample at But follow-up as whole after of and we cancer. cohort do So and lung few cell the Stage time, do we XX%, in surgery. can surgery. normal sequencing sampling and non-small collected paired time. patients And as the very them, also well after And enrolled X you are Stage of X. X tissue most that basically days as like the days tumor collected Stage we surgery. blood X about And patients, preoperative adjacent XXX a there's we here, collect at exome And XX a on tissue, we the
blood time when months the we to a the X follow-up doctor back every year after sample. up, patient X if or So see possible, like goes collect
And then at kind to different status. of look approach we used X MRD
we this one kind the to -- can MRD think about doing we're exome tumor-informed either the whole well a calling fixed sequencing-based a assays. tumor-agnostic brPROPHET to also it sequencing top of of do panel design as is using this comparison, assay personalized or first the showing basically But target right, kind on determine assay. In MRD also you way. tumor as it's call The
So compared basically, sequencing. many whole load exome smaller sequencing mutation more fixed-panel potential gave relatively to us target site
XX, major So basically move conclusion observation seen. have several using this data, we by Page to are let's there
to XX to actually, why, from basically very if percentage that's perfect close you look ideally, able you blood sample is every preoperative this -- Page coming And detection be is sample, a So untreated at untreated get like the assay should your plasma will showing patients' patients. see is blood of if patient so the from sensitivity. coming high
III. can highest And here, Stage you III, to sensitivity Stage definitely the As the grew sensitivity. you've got from see up -- at detection sensitivity Stage Ia
tumor-agnostic orange the sequencing. is well can as see outperformed the PROPHET our But which as the assay, as tumor-informed color, it you representing so panel sequencing fixed-panel here,
X (sic) all III with the right in see and here, the [ you the see on fraction one, showing page, we IIb detectability, So totally, plot which B also shown can basically the showing at Stage you X, the Ib already patient ], Stage box is Stage samples, red the with positivity. see MRD-positive we is here And XX%, XX% in XX% as for see ctDNA panel background. as the can highest Stage
than you but the way orange just XX lower. of the sensitivity magnitude X trying patients low right, X if means tumor the But lower -- there's trying very positive low showing kind positive color, if importance, only only allele brPROPHET -- assay patients look all This preoperative the those reflects get the detection the MRD frequency, ctDNA which to actually at It's confirm fraction the patients. status. to fraction is in patient, very on
this course, is Of the preoperative.
the with relapse at Basically, survival. postoperative status the XX. real and a we use disease-free this come of the sample with status So MRD to also associated to let's potential move the Page look determine blood to kind
using On timepoint XX the B, days which -- which is which C. landmark surgery X as the are days left or is timepoint, we is page, or timepoint after basically
as the very see, If patient, to follow-up for timepoint like MRD-negative, check is MRD-positive to you to look disease-free that at XX.X, showing for show a you to one survival which DFS difference. percentage, ratio is can patient, if the and which to compared significant landmark even the timepoint way reached survival C have survival this you curve, -- up pretty ratio showing will you're HR the days, reached X,XXX timepoint, higher -- the HR basically
for analysis. timepoint if we're right on But showing MRD-positive. multiple there's we collection, assessment patients any the is if of deem patient collected plasma on panel, post MRD then the is we -- MRD-negative. longitudal And surgery point the any all side utilizing basically the sample. And This on samples MRD-negative, page MRD-positive right from deem the signal as basically blood time
timepoint be gives also of us As it separation survival. the lot will confidence, a the disease-free even separation lot other surveillance multiple reflect collection, just us you a publications. usually can Continuous give of That see better. of here, requires better
basically it's basically III, the I So trend. and also showing or related now very Stage similar to Stage II
value lung So in assay good a personalized Cell I how example summary, give even also Cancer the very II and showing Stage basically, prognosis this on a III. can in us and good paper the WES-based cell gave cancer, published MRD very non-small
different other to and trying to treatment to look of trying And at this to prognosis cancer so of predictive kind we we and course, still working on on the selection multiple only not types kind also keep working assessment. or hospitals, also and assay of value, with of top-tier if want kind any value we see drug clinical effectiveness utility any related --
my Thank concludes you. the moderator. that to So Back part.
